Skip to main content
SpringerLink
Log in

Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas

  • Case Report
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of the present study was to investigate the effect of a new galenic injectable form of bromocriptine (Parlodel LA), characterized by sustained release of bromocriptine for 4–6 weeks, in 3 patients with prolactin-secreting macroadenomas through a 42-day follow-up. The following parameters were considered: decrease of plasma prolactin levels, reduction of tumor size studied by seriate CT scan controls and recovery of eventual visual fields impairments. Parlodel LA induced a sharp decrease of plasma prolactin levels for at least 42 days, without reaching normal values. This treatment also caused a rapid and marked shrinkage of tumors in all patients. Moreover, in two patients with constriction of visual fields a clear and progressive improvement in one and only a slight amelioration in the other were observed. There were almost no side effects except for mild nausea in one patient and transient orthostatic in another. These results demonstrate that Parlodel LA produces a long-lasting reduction of plasma prolactin levels and a rapid shrinkage of the tumor with almost no side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Cheung R.J., Jaffe R., Joplin J., Robbins R.J., Tyson J., Thorner M.O., and the Bromocriptine Study Group. Bromocriptine as primary therapy for prolactin secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.

    Article  PubMed  CAS  Google Scholar 

  2. Thorner M.O., Martin W.H., Rogol A.D., Morris J.L., Perryman R.L., Conway B.P., Howards S.S., Wolffman M.G., MacLeod R.M. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J. Clin. Endocrinol. Metab. 51: 438, 1980.

    Article  PubMed  CAS  Google Scholar 

  3. Vance M.L., Evans W.S., Thorner M.O. Drugs five years later. Bromocriptine. Ann. Intern. Med. 100: 78, 1984.

    Article  PubMed  CAS  Google Scholar 

  4. Lancranjan I., Rolland R., L’Hermite M. Data with a new galenical form of bromocriptine in suppression of lactation. 7th Int. Congress of Endocrinology, Quebec City, Abs. 1307, 1984.

  5. Chavez H., Valsamis J., Westelinck K., Haemers M., L’Hermite M. Inhibition of puerperal lactation by means of a single injection of bromocriptine retard. 4th Int. Congress on Prolactin, Charlottesville, Abs. 141, 1984.

  6. Ciccarelli E., Ghigo E., Andreis M., Mazza E., Bertagna A., Molinatti G.M., Massara F., Lancranjan I., Camanni F. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia. Int. Congress Endocrinology ’85, Turin, Abs. 98, 1985.

  7. Cavagnini F., Lancranjan I., Maraschini C., Invitti C., Brunani A., Falsetti L., Motta T. Effectiveness of a long-acting preparation of bromocriptine in prolactin and/or growth hormone secreting adenomas. J. Endocrinol. Invest. 8 (suppl. 3): 190, 1985.

    Google Scholar 

  8. Grossman A., Wass J.A.H., Besser G.M. A new injectable form of bromocriptine for the treatment of hyperprolactinemia and acromegaly. J. Endocrinol. Invest. 8 (suppl. 3): 104, 1985.

    Google Scholar 

  9. L’Hermite M., Copinschi G., Couturier E., Stevenaert A. Primary treatment of macroprolactinomas by injectable bromocriptine retard. J. Endocrinol. Invest. 8 (suppl. 3): 191, 1985.

    Google Scholar 

  10. Lancranjan I., Montini M., Pagani. Data with a new galenical form of bromocriptine in patients with prolactinomas. 67th Annual Meeting of the Endocrine Society, Baltimore, Abs. 164, 1985.

  11. Montini M., Lancranjan I., Ferrari L., Salmoiraghi M., Pagani M.D., Gianola D., Parodi D., Pagani G. Data with a new galenic form of bromocriptine in patients with microprolactinomas. Int. Congress Endocrinology ’85, Turin, Abs. 108, 1985.

  12. Delpozo E., Schluter K., Nuesch E., Rosenthaler J., Kerp L. Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. Eur. J. Clin. Pharmacol. 29: 615, 1986.

    Article  CAS  Google Scholar 

  13. Grossman A., Ross R., Wass J.A.H., Besser G.M. Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin. Endocrinol. (Oxf.) 24: 231, 1986.

    Article  CAS  Google Scholar 

  14. Montini M., Pagani G., Gianola D., Pagani M.D., Salmoiraghi M., Ferrari L., Lancranjan I. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine. J. Clin. Endocrinol. Metab. 63: 266, 1986.

    Article  PubMed  CAS  Google Scholar 

  15. Tindall G.T., Kovacs K., Horvath E., Thorner M.O. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J. Clin. Endocrinol. Metab. 55: 1178, 1982.

    Article  PubMed  CAS  Google Scholar 

  16. Bassetti M., Spada A., Pezzo G., Giannattasio G. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J. Clin. Endocrinol. Metab. 58: 268, 1984.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Farmacologia Sperimentale e Clinica, II Facoltà di Medicina e Chirurgia, Università di Napoli, Via Sergio Pansini 5, 80131, Napoli, Italy, Napoli, Italy

    G. Schettini

  2. Istituto di Scienze Endocrinologiche, Napoli, Italy

    G. Lombardi, B. Merola, P. Miletto & C. Fariello

  3. Istituto di Radiologia, Napoli, Italy

    S. Cirillo

  4. Istituto di Oculistica, II Facoltà di Medicina e Chirurgia, University of Napoli, 80100, Napoli, Italy

    R. Fusco

  5. Department of Neuroendocrinology, Clinical Research, Sandoz Ltd., Basle, Switzerland

    I. Lancranjan

Authors
  1. G. Schettini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Merola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Miletto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Fariello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Cirillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I. Lancranjan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schettini, G., Lombardi, G., Merola, B. et al. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas. J Endocrinol Invest 11, 47–51 (1988). https://doi.org/10.1007/BF03350096

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350096

En]Keywords

Search

Navigation